All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

Today we're talking software with Carl Press, a partner at Thoma Bravo.

Why he matters: Press co-leads Thoma's Explore platform, focused on high-growth lower-middle-market software and technology businesses.

Press' responses were lightly edited for clarity and length.

What areas of health technology and software are most exciting?

Software continues to disrupt every aspect of health care — how physicians and nurses administer care, how hospitals reduce cost, how pharmaceutical companies facilitate clinical trials, etc.

Last year, we invested in Circle CVI, the global leader in cardiovascular imaging solutions, which is an excellent example of an emerging disruptor. Circle CVI operates in a large and rapidly growing clinical area, has incredibly sticky customers with big budgets, and is quickly becoming the industry standard for care providers (in this case, cardiologists and radiologists).

The pace and volume of deal activity in the mid-market has slowed in the past two quarters. Valuations have pulled back, particularly for unprofitable businesses, but the adjustment is not as dramatic as in the public markets.

High-quality profitable software businesses in the mid-market are scarce, and capital is abundant, so these businesses are attracting a lot of attention and still receiving premium valuations.

What’s the financing environment looking like?

Private direct lenders remain active in software, particularly for high-quality cashflow-based loans. We don’t use much debt to finance our transactions, but to-date we haven’t had issues tapping the debt capital markets (albeit at much higher rates).

What is one tailwind that makes you optimistic and a headwind that makes you cautious?

Labor dynamics have been both a tailwind and a headwind.

As a tailwind, we’ve seen a reduction in Big Tech’s aggressive poaching of talent across the software industry, which had been disruptive for our companies over the past few years (particularly since COVID/remote work began).

As a headwind, high-quality engineering talent globally remains scarce and expensive, and we’re not anticipating that trend to reverse anytime soon.

Expert Voices: Carl Press of Thoma Bravo

Software continues to disrupt every aspect of health care.

Photo illustration of Carl Press, partner on the Explore team at Thoma Bravo, surrounded by abstract shapes.

Photo illustration: Gabriella Turrisi/Axios. Photo: courtesy of Thoma Bravo

Health tech

Today we&#x27;re talking software with Carl Press, a partner at Thoma Bravo.Why he matters: Press co-leads Thoma&#x27;s Explore platform, focused on high-growth lower-middle-market software and technology businesses.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

c-suite

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

boulder

kansas-city

austin

chicago

dallas

detroit

washington-dc

atlanta

indianapolis

nashville

nw-arkansas

columbus

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

arapahoe

douglas

san-diego

tampa-bay

portland

cleveland

axios-local

axios-pro

axios-live

the-axios-show

Expert Voices: Carl Press of Thoma Bravo

What to read next